{"schema_version":"secwatch.filing_event.v1","accession":"0001447362-23-000036","form_type":"8-K","ticker":"CSTL","cik":"0001447362","company_name":"CASTLE BIOSCIENCES INC","filed_at":"2023-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.043187+00:00","generated_at":"2026-06-18T21:49:02.132157+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Castle Biosciences FY2022 revenue $137M (+46% YoY); guides FY2023 revenue $170-180M","bullets":["Full-year 2022 revenue $137.0M, up 46% from $94.1M; test reports 44,419, up 58%.","Q4 2022 revenue $38.3M (+53% YoY); test reports 12,644 (+53%).","Net loss $67.1M (incl. $36.3M stock compensation) vs $31.3M loss in 2021.","Adjusted EBITDA -$42.6M vs -$14.9M; cash and investments $258.6M at year-end.","FY2023 revenue outlook $170-180M; reaffirms 2025 targets of $255-330M revenue and cash flow positivity."],"urls":{"canonical":"https://secwatch.observer/filing/0001447362-23-000036","json":"https://secwatch.observer/filing/0001447362-23-000036.json","markdown":"https://secwatch.observer/filing/0001447362-23-000036.md","text":"https://secwatch.observer/filing/0001447362-23-000036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447362/000144736223000036/0001447362-23-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447362/000144736223000036/cstl-20230228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T21:49:02.132157+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d78bdbea36e827e404b876bbaca8fd5693b33483","claim":"CASTLE BIOSCIENCES INC reported financial results for the fourth quarter and year ended December 31, 2022.","evidence_excerpt":"On February 28, 2023, Castle Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1447362/000144736223000036/0001447362-23-000036-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}